scholarly journals Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatment

2016 ◽  
Vol 5 (1) ◽  
pp. 23-26 ◽  
Author(s):  
ELEFTHERIA HATZIMICHAEL ◽  
KONSTANTINOS LAGOS ◽  
AMALIA VASSOU ◽  
DORA GOUGOPOULOU ◽  
ALEXANDRA PAPOUDOU-BAI ◽  
...  
Keyword(s):  
Myelodysplastic Syndrome ◽  
Jak2 V617f ◽  
Jak2 V617f Mutation ◽  
Durable Response ◽  
Discontinuation Of Treatment ◽  
V617f Mutation ◽  
5Q Deletion

scholarly journals The lack of association between JAK2 V617F mutation and myelodysplastic syndrome with or without myelofibrosis

Leukemia ◽  
2006 ◽  
Vol 20 (6) ◽  
pp. 1165-1165 ◽  
Author(s):  
S-F Yip ◽  
C-C So ◽  
Ay-Y Chan ◽  
Hs-Y Liu ◽  
Ts-K Wan ◽  
...  
Keyword(s):  
Myelodysplastic Syndrome ◽  
Jak2 V617f ◽  
Jak2 V617f Mutation ◽  
V617f Mutation

P-169 Presence of JAK2 V617F mutation in myeloproliferative and myelodysplastic syndrome patients

2013 ◽  
Vol 37 ◽  
pp. S99-S100
Author(s):  
F. Duarte ◽  
T. Santos ◽  
M. Barbosa ◽  
T. Santos ◽  
R. Gonçalves
Keyword(s):  
Myelodysplastic Syndrome ◽  
Jak2 V617f ◽  
Jak2 V617f Mutation ◽  
V617f Mutation

P124 The prevalence of JAK2 V617F mutation in myelodysplastic syndrome

Blood Reviews ◽  
2007 ◽  
Vol 21 ◽  
pp. S126
Author(s):  
M. Radič Antolic ◽  
R. Zadro ◽  
P. Rončevič ◽  
S. Bašič Kinda ◽  
B. Labar
Keyword(s):  
Myelodysplastic Syndrome ◽  
Jak2 V617f ◽  
Jak2 V617f Mutation ◽  
V617f Mutation

355 5q deletion acquisition was associated with myelodysplastic evolution in patient with essential thrombocythemia JAK2 V617F mutation

2011 ◽  
Vol 35 ◽  
pp. S143
Author(s):  
R.A.D. Assis ◽  
F.P.D.S. Santos ◽  
D.D.C. Pasqualin ◽  
P.A.A. Silveira ◽  
N. Hamerschlak ◽  
...  
Keyword(s):  
Essential Thrombocythemia ◽  
Jak2 V617f ◽  
Jak2 V617f Mutation ◽  
V617f Mutation ◽  
5Q Deletion

Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation

2010 ◽  
Vol 51 (10) ◽  
pp. 1941-1943 ◽  
Author(s):  
Gemma Azaceta ◽  
Maria J. Calasanz ◽  
Victoria Dourdil ◽  
Elena Bonafonte ◽  
Isabel Izquierdo ◽  
...  
Keyword(s):  
Myelodysplastic Syndrome ◽  
Jak2 V617f ◽  
Jak2 V617f Mutation ◽  
V617f Mutation

Is JAK2 V617F mutation more than a diagnostic index?

2009 ◽  
Vol 33 (1) ◽  
pp. 67-73 ◽  
Author(s):  
Issa J. Dahabreh ◽  
Katerina Zoi ◽  
Stavroula Giannouli ◽  
Christine Zoi ◽  
Dimitrios Loukopoulos ◽  
...  
Keyword(s):  
Jak2 V617f ◽  
Jak2 V617f Mutation ◽  
V617f Mutation ◽  
Diagnostic Index

scholarly journals CRISPR/Cas12a-Based Ultrasensitive and Rapid Detection of JAK2 V617F Somatic Mutation in Myeloproliferative Neoplasms

Biosensors ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 247
Author(s):  
Miaomiao Chen ◽  
Chunhua Zhang ◽  
Zhiqing Hu ◽  
Zhuo Li ◽  
Menglin Li ◽  
...  
Keyword(s):  
Detection System ◽  
Myeloproliferative Neoplasms ◽  
Cost Effective ◽  
Jak2 V617f ◽  
Jak2 V617f Mutation ◽  
Minimum Detectable Concentration ◽  
Lateral Flow Strip ◽  
Whole Process ◽  
Detectable Concentration ◽  
V617f Mutation

The JAK2 V617F mutation is a major diagnostic, therapeutic, and monitoring molecular target of Philadelphia-negative myeloproliferative neoplasms (MPNs). To date, numerous methods of detecting the JAK2 V617F mutation have been reported, but there is no gold-standard diagnostic method for clinical applications. Here, we developed and validated an efficient Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated protein 12a (Cas12a)-based assay to detect the JAK2 V617F mutation. Our results showed that the sensitivity of the JAK2 V617F/Cas12a fluorescence detection system was as high as 0.01%, and the JAK2 V617F/Cas12a lateral flow strip assay could unambiguously detect as low as 0.5% of the JAK2 V617F mutation, which was much higher than the sensitivity required for clinical application. The minimum detectable concentration of genomic DNA achieved was 0.01 ng/μL (~5 aM, ~3 copies/μL). In addition, the whole process only took about 1.5 h, and the cost of an individual test was much lower than that of the current assays. Thus, our methods can be applied to detect the JAK2 V617F mutation, and they are highly sensitive, rapid, cost-effective, and convenient.

scholarly journals The study of Jak2 V617F mutation in polycythemia vera with zebrafish model

Cell Research ◽  
2008 ◽  
Vol 18 (S1) ◽  
pp. S141-S141
Author(s):  
Alvin CH Ma ◽  
Alice MS Cheung ◽  
Alister C Ward ◽  
Wing-Yan Au ◽  
Yok-Lam Kwong ◽  
...  
Keyword(s):  
Polycythemia Vera ◽  
Jak2 V617f ◽  
Jak2 V617f Mutation ◽  
Zebrafish Model ◽  
V617f Mutation

scholarly journals A new case of dic(1;15) in essential thrombocythaemia with JAK2 V617F mutation

2012 ◽  
Author(s):  
Pereira Velloso ED Rodrigues ◽  
Ratis C Alonso ◽  
RK Kishimoto ◽  
Oliveira D Aquilino ◽  
Misael NC de Sousa ◽  
...  
Keyword(s):  
Jak2 V617f ◽  
Jak2 V617f Mutation ◽  
Essential Thrombocythaemia ◽  
V617f Mutation
Sign in / Sign up

Export Citation Format

Share Document